MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
- PMID: 26399658
- DOI: 10.1038/nrc4000
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Similar articles
-
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.Pharmacol Ther. 2018 Jul;187:45-60. doi: 10.1016/j.pharmthera.2018.02.007. Epub 2018 Feb 16. Pharmacol Ther. 2018. PMID: 29454854 Review.
-
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.Semin Oncol. 2015 Dec;42(6):849-62. doi: 10.1053/j.seminoncol.2015.09.023. Epub 2015 Sep 24. Semin Oncol. 2015. PMID: 26615130 Free PMC article. Review.
-
ERK1/2 can feedback-regulate cellular MEK1/2 levels.Cell Signal. 2015 Oct;27(10):1939-48. doi: 10.1016/j.cellsig.2015.07.003. Epub 2015 Jul 9. Cell Signal. 2015. PMID: 26163823 Free PMC article.
-
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.Sci Signal. 2011 Mar 29;4(166):ra17. doi: 10.1126/scisignal.2001752. Sci Signal. 2011. Corrected and republished in: Sci Signal. 2011;4(170):er2. doi: 10.1126/scisignal.4170er2. PMID: 21447798 Corrected and republished.
-
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.Nat Struct Mol Biol. 2004 Dec;11(12):1192-7. doi: 10.1038/nsmb859. Epub 2004 Nov 14. Nat Struct Mol Biol. 2004. PMID: 15543157
Cited by
-
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.Br J Cancer. 2024 May 31. doi: 10.1038/s41416-024-02727-2. Online ahead of print. Br J Cancer. 2024. PMID: 38822146
-
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Int J Mol Sci. 2024 Apr 24;25(9):4633. doi: 10.3390/ijms25094633. Int J Mol Sci. 2024. PMID: 38731852 Free PMC article. Review.
-
Reversine inhibits proliferation and induces apoptosis of human osteosarcoma cells through targeting MEK1.J Bone Oncol. 2024 Apr 17;46:100601. doi: 10.1016/j.jbo.2024.100601. eCollection 2024 Jun. J Bone Oncol. 2024. PMID: 38706714 Free PMC article.
-
Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib.Cancers (Basel). 2024 Mar 5;16(5):1056. doi: 10.3390/cancers16051056. Cancers (Basel). 2024. PMID: 38473413 Free PMC article. Review.
-
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.Clin Cancer Res. 2024 May 1;30(9):1739-1749. doi: 10.1158/1078-0432.CCR-23-3135. Clin Cancer Res. 2024. PMID: 38456660 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
- BBS/E/B/0000H248/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- BBS/E/B/0000H151/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- BBS/E/B/0000C199/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- BBS/E/B/000C0417/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- 14867/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous